To appraise the clinical and cost effectiveness of venetoclax in combination with rituximab within its marketing authorisation for treating relapsed or refractory chronic lymphocytic leukaemia.
Status In progress
Process STA
ID number 1097

Provisional Schedule

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 12 January 2018 - 09 February 2018
Expected publication 20 February 2019

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance